Clinical trialsCompany release

Longeveron seeks FDA meeting after ELPIS II miss and starts strategic alternatives review

🇺🇸 Longeveron Inc. (LGVN) · Thu 12 Nov 2026

The cell therapy developer reported that laromestrocel missed its primary endpoint in infants with hypoplastic left heart syndrome, and is now weighing a sale or merger.

Longeveron has asked the US Food and Drug Administration for a meeting to discuss next steps for laromestrocel in hypoplastic left heart syndrome (HLHS), after the Phase 2b ELPIS II trial missed its primary endpoint. The company disclosed the request on 12 November 2026 alongside its results for the quarter ended 30 September.

The primary endpoint was right ventricular ejection fraction (RVEF), and the study did not meet it. A secondary signal pointed the other way: major adverse cardiac events (MACE) were lower in the treated group, with one event against eight in patients receiving standard of care.

Longeveron has also begun a review of strategic alternatives, which includes the possibility of a sale or merger. It has appointed Lucid Capital Markets as its adviser for the process. The company said it has introduced cash conservation measures.

The source material available gives no further detail on the size of the trial, the statistical significance of the MACE difference, the timing of the FDA meeting or the company's cash position. Those points were not stated in the information provided.

What it means for your team

  • A missed primary endpoint alongside a favourable MACE count leaves the regulatory path unclear, which makes the planned FDA meeting the key near-term event for the programme.
  • Teams tracking paediatric cardiac and cell-therapy development should note that the MACE difference of one versus eight events comes from a trial that missed its primary endpoint, so it is hard to treat as confirmatory.
  • The strategic review and cash conservation steps signal possible changes in programme ownership or continuity, which partners and market-access planners may need to monitor.

Company's press release (SEC filing): Longeveron Inc. ↗

Article written by VigiEye from the official source (Longeveron Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →